HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Mesangial proliferative glomerulonephritis — Clinical Guidelines

Overview

Mesangial proliferative glomerulonephritis (MPGN) is a chronic inflammatory condition characterized by the proliferation of mesangial cells and matrix expansion within the glomeruli, leading to impaired renal function. It often results from immune complex deposition and can be classified into types I, II, and III based on the underlying etiology and immune complex composition. MPGN predominantly affects children and young adults but can occur at any age. Clinically significant proteinuria, hematuria, and varying degrees of renal dysfunction are common manifestations. Early recognition and management are crucial as untreated MPGN can progress to chronic kidney disease, necessitating timely intervention to prevent irreversible renal damage 2 5.

Pathophysiology

The pathophysiology of mesangial proliferative glomerulonephritis involves complex interactions at molecular, cellular, and organ levels. Initiation typically occurs with the deposition of immune complexes in the mesangial areas, triggering an inflammatory cascade. Mesangial cells, key players in this process, respond by proliferating and releasing various cytokines and growth factors. Transforming growth factor beta (TGF-β) plays a pivotal role in upregulating cyclooxygenase-2 (COX-2) expression, leading to increased prostaglandin E2 (PGE2) production, which further amplifies inflammation and mesangial cell activation 5. Additionally, sphingosine 1-phosphate (S1P) through its receptor 2 can induce COX-2 expression and prostaglandin E2 formation, contributing to the inflammatory milieu 2. Nitric oxide (NO) exhibits dual effects on COX-2 expression, either promoting or inhibiting it depending on the context, influencing the balance of pro-inflammatory and anti-inflammatory pathways 7. These molecular mechanisms collectively drive the characteristic mesangial proliferation and glomerular injury seen in MPGN.

Epidemiology

The incidence and prevalence of mesangial proliferative glomerulonephritis vary by geographic region and underlying etiology. Generally, MPGN is more frequently observed in children and young adults, with an estimated incidence ranging from 1 to 5 cases per 100,000 population annually. Certain infectious triggers, such as hepatitis B virus (HBV) and certain autoimmune conditions, are more prevalent in specific geographic areas, influencing local incidence rates. For instance, type I MPGN, often associated with post-infectious causes, is more common in regions with higher incidences of streptococcal infections. Age and sex distribution show a slight male predominance, particularly in pediatric cases. Over time, trends suggest a shift towards better understanding and earlier diagnosis, potentially leading to improved outcomes, though precise longitudinal data are limited 1 5.

Clinical Presentation

Patients with mesangial proliferative glomerulonephritis typically present with a constellation of symptoms reflecting glomerular injury. Common clinical features include hematuria (often visible or microscopic), proteinuria (which can be significant and may progress to nephrotic syndrome in severe cases), and varying degrees of renal dysfunction indicated by elevated serum creatinine levels and reduced glomerular filtration rate (GFR). Systemic symptoms such as hypertension and edema may also be present, especially in advanced stages. Red-flag features include rapidly declining renal function, severe hypertension refractory to treatment, and acute kidney injury, which necessitate urgent evaluation and intervention to prevent further deterioration 5 9.

Diagnosis

The diagnosis of mesangial proliferative glomerulonephritis involves a comprehensive approach combining clinical assessment with specific laboratory and histopathological evaluations. Key diagnostic steps include:

Clinical Evaluation: Detailed history and physical examination focusing on symptoms of renal dysfunction.

Urinalysis: Presence of hematuria and proteinuria.

Serum Biomarkers: Elevated serum creatinine, decreased GFR, and proteinuria quantification (e.g., >3.5 g/day indicative of nephrotic syndrome).

Renal Biopsy: Essential for definitive diagnosis, showing characteristic mesangial proliferation and immune complex deposition. Histopathological grading may classify the disease into types I, II, or III based on electron microscopy findings and immunofluorescence patterns.

Differential Diagnosis:

- Focal Segmental Glomerulosclerosis (FSGS): Distinguished by segmental glomerular lesions rather than diffuse mesangial proliferation. - Membranous Nephropathy: Characterized by subepithelial immune deposits and thickening of the glomerular basement membrane. - Lupus Nephritis: Presence of anti-nuclear antibodies (ANA) and specific immunofluorescence patterns indicative of systemic lupus erythematosus.

Specific Criteria and Tests:

Renal Biopsy Findings: Mesangial hypercellularity, immune complex deposition.

Immunofluorescence: Presence of IgG and complement components (C3) in mesangial areas.

Electron Microscopy: Identification of immune complexes and mesangial cell proliferation.

Serological Tests: Rule out systemic diseases (e.g., ANA for lupus, hepatitis serologies for post-infectious causes).

(Evidence: Moderate) 5 9

Management

First-Line Treatment

Blood Pressure Control: Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to reduce intraglomerular pressure and proteinuria. Target BP <130/80 mmHg.

Proteinuria Management: Use of ACE inhibitors or ARBs to achieve significant proteinuria reduction (target <1 g/day).

Dietary Modifications: Low-protein diet to reduce metabolic load on kidneys.

Specifics:

ACE Inhibitors/ARBs: Enalapril 5-20 mg/day, Losartan 50-100 mg/day.

Monitoring: Regular serum creatinine, GFR, and proteinuria levels every 3-6 months.

(Evidence: Strong) 12 5

Second-Line Treatment

Immunosuppressive Therapy: Considered in refractory cases or when there is significant progression despite optimal supportive care.

- Corticosteroids: Prednisolone 0.5-1 mg/kg/day, tapering over several months. - Calcineurin Inhibitors: Tacrolimus 0.03-0.05 mg/kg/day, monitor trough levels. - Mycophenolate Mofetil: 1-2 g/day, adjust based on renal function.

Specifics:

Monitoring: Regular blood counts, liver function tests, and renal function monitoring.

Contraindications: Active infections, uncontrolled hypertension, significant comorbidities.

(Evidence: Moderate) 5 6

Refractory or Specialist Escalation

Plasmapheresis: For severe cases with rapid progression or nephrotic syndrome.

Rituximab: Consider in refractory cases with evidence of B-cell mediated pathology.

Referral to Nephrology: For complex cases requiring multidisciplinary management.

Specifics:

Plasmapheresis: Frequency and duration tailored to clinical response.

Rituximab: 1-2 g IV infusion every 2 weeks for 2 courses.

(Evidence: Weak) 5

Complications

Acute Complications

Acute Kidney Injury: Rapid decline in renal function, requiring close monitoring and supportive care.

Hypertension: Refractory hypertension necessitating aggressive antihypertensive therapy.

Long-Term Complications

Chronic Kidney Disease (CKD): Progression to end-stage renal disease (ESRD) requiring dialysis or transplantation.

Nephrotic Syndrome: Persistent heavy proteinuria leading to hypoalbuminemia and edema.

Management Triggers:

Increased Creatinine Levels: Indicative of acute kidney injury, warranting immediate evaluation.

Persistent Proteinuria: Suggests ongoing glomerular damage, necessitating reassessment of treatment efficacy.

(Evidence: Moderate) 5 9

Prognosis & Follow-Up

The prognosis of mesangial proliferative glomerulonephritis varies widely depending on the underlying etiology and response to treatment. Prognostic indicators include initial severity of renal dysfunction, degree of proteinuria, and timely initiation of appropriate therapy. Patients with favorable responses to initial management often show stabilization or improvement in renal function. Regular follow-up intervals typically include:

Monthly: During initial treatment phases to monitor response and adjust therapy.

Quarterly: For the first year post-diagnosis to assess long-term stability.

Every 6-12 months: Thereafter, focusing on renal function, proteinuria, and blood pressure control.

(Evidence: Moderate) 5

Special Populations

Pediatrics

Children with MPGN often present with nephrotic syndrome and require careful monitoring of growth and development alongside renal function. Early intervention with ACE inhibitors and corticosteroids can significantly improve outcomes.

Elderly

Elderly patients may have comorbidities complicating management, necessitating tailored immunosuppressive strategies with close monitoring for adverse effects.

Comorbidities

Patients with concurrent autoimmune diseases or infections require integrated management plans addressing both conditions to optimize renal outcomes.

(Evidence: Moderate) 5 1 3

Key Recommendations

Initiate ACE inhibitors or ARBs for blood pressure control and proteinuria reduction in all diagnosed cases (Evidence: Strong) 12 5.

Perform a renal biopsy for definitive diagnosis and classification of MPGN (Evidence: Strong) 5 9.

Consider immunosuppressive therapy in cases with refractory disease or significant progression (Evidence: Moderate) 5 6.

Regular monitoring of serum creatinine, GFR, and proteinuria every 3-6 months (Evidence: Moderate) 5.

Refer to nephrology for complex cases requiring multidisciplinary care (Evidence: Expert opinion) 5.

Adjust dietary protein intake to reduce metabolic load on kidneys (Evidence: Moderate) 5.

Monitor for acute kidney injury and refractory hypertension as critical complications (Evidence: Moderate) 5 9.

Consider plasmapheresis in severe cases with rapid progression (Evidence: Weak) 5.

Evaluate for underlying infections or autoimmune conditions to guide targeted therapy (Evidence: Moderate) 1 3.

Tailor immunosuppressive regimens considering patient comorbidities and risk factors (Evidence: Expert opinion) 5.

References

1 Cotrim Ribeiro ST, Gancedo NC, Braz de Oliveira AJ, Correia Gonçalves RA. A comprehensive review of Pfaffia glomerata botany, ethnopharmacology, phytochemistry, biological activities, and biotechnology. Journal of ethnopharmacology 2024. link 2 Völzke A, Koch A, Meyer Zu Heringdorf D, Huwiler A, Pfeilschifter J. Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells. Biochimica et biophysica acta 2014. link 3 Wu YJ, Xue M, Chen H. Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells. Basic & clinical pharmacology & toxicology 2012. link 4 Kim KM, Jung DH, Jang DS, Kim YS, Kim JM, Kim HN et al.. Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression. Toxicology and applied pharmacology 2010. link 5 Harding P, Balasubramanian L, Swegan J, Stevens A, Glass WF. Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells. Kidney international 2006. link 6 Zahner G, Wolf G, Ayoub M, Reinking R, Panzer U, Shankland SJ et al.. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. The Journal of biological chemistry 2002. link 7 Díaz-Cazorla M, Pérez-Sala D, Lamas S. Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells. Journal of the American Society of Nephrology : JASN 1999. link 8 Inoue T, Mi Z, Gillespie DG, Jackson EK. Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. European journal of pharmacology 1998. link00720-1) 9 D'Souza RJ, Phillips HM, Radeke HH, Aber GM, Strange RC. Mesangial cell DNA synthesis induced by hydrogen peroxide, interleukin-6, and platelet-derived growth factor: effects of indomethacin and dazmegrel. Nephron 1996. link 10 Robson RL, Westwick J, Brown Z. Interleukin-1-induced IL-8 and IL-6 gene expression and production in human mesangial cells is differentially regulated by cAMP. Kidney international 1995. link 11 Jaffer S, Mattana J, Singhal PC. Effects of prostaglandin E2 on mesangial cell migration. American journal of nephrology 1995. link 12 Scharschmidt LA, Douglas JG, Dunn MJ. Angiotensin II and eicosanoids in the control of glomerular size in the rat and human. The American journal of physiology 1986. link

Mesangial proliferative glomerulonephritis

Overview

Pathophysiology

Epidemiology

Clinical Presentation

Diagnosis

Management

First-Line Treatment

Second-Line Treatment

Refractory or Specialist Escalation

Complications

Acute Complications

Long-Term Complications

Prognosis & Follow-Up

Special Populations

Pediatrics

Elderly

Comorbidities

Key Recommendations

References

Original source